Core Viewpoint - The FDA has issued warning letters to over 100 drug companies, including Hims & Hers, Eli Lilly, and Novo Nordisk, for making "false or misleading claims" about weight-loss products following an order from President Trump aimed at regulating drug advertising [1][2]. Group 1: FDA Warnings - The FDA's warning letters target the "unlawful sale of unapproved and misbranded drugs" sold online [2]. - Hims & Hers received a letter concerning its compounded semaglutide products, with the FDA highlighting misleading claims that these products are equivalent to FDA-approved drugs [2][3]. - Novo Nordisk was warned about misleading content related to its weight loss drugs featured in an Oprah Winfrey special, with similar warnings issued to Eli Lilly regarding its drugs [3][4]. Group 2: Stock Performance - Following the FDA warnings, shares of Hims & Hers fell nearly 6%, although the stock is still up 12.7% for the month [5]. - In contrast, stocks of Eli Lilly and Novo Nordisk showed resilience, trading up 2% and 2.7% respectively [5]. Group 3: Regulatory Context - President Trump's recent order aims to enhance transparency in drug advertising, particularly regarding the risks associated with pharmaceutical drugs [7]. - The order is part of a broader initiative against pharmaceutical companies, including demands for price reductions to align with the lowest drug costs in other developed countries [7].